<DOC>
	<DOCNO>NCT01924169</DOCNO>
	<brief_summary>The goal clinical research study learn lenalidomide increase level immunoglobulin ( part blood may help improve immune system 's function ) and/or improve protective effect flu pneumonia vaccine patient CLL .</brief_summary>
	<brief_title>Lenalidomide Immune Adjuvant Patient 's With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take lenalidomide mouth Monday , Wednesday Friday 3 month . In order participate study must register follow requirement Revlimid REMS™ program Celgene Corporation . This program provide education counsel risk fetal exposure , blood clot reduce blood count . You require receive counseling every 28 day treatment lenalidomide , follow pregnancy test birth control requirement program appropriate take telephone survey regard compliance program . Depending respond drug , 3 month , either : °Take lenalidomide every Monday , Wednesday Friday 3 month on/3 month schedule . You repeat process 2 year . °Take lenalidomide every day extra 3 month . If respond well , take lenalidomide every day 3 month , next 3 month stop drug . You repeat process 2 year . You swallow lenalidomide capsule whole water . Do open , crush , break lenalidomide capsule . If touch broken lenalidomide capsule , wash area body soap water . If miss dose lenalidomide , le 12 hour since regular dose time , take soon remember . If 12 hour , skip miss dose . Do take 2 dos time . If take much lenalidomide overdose , call healthcare provider right away . If vomit dose , take another dose . You also receive vaccine flu ( Trivalent Fluzone ) 1 time year . If receive one last 5 year , receive vaccine pneumonia ( Pneumovax ) month 6 21 . You receive vaccine injection skin . Study Visits : Before first dose study drug : °Blood ( 2 teaspoon ) draw test cytokine ( protein may affect immune system ) test immune system . If able become pregnant , 1 time week first 4 week every 28 day treatment , blood ( 1 teaspoon ) urine pregnancy test . While take lenalidomide , blood ( 1 teaspoon ) drawn routine test every 2-4 week . At 3 month ( +/- 3 week ) : - You physical exam . - Blood ( 1 teaspoon ) drawn routine test . Before flu vaccine , blood ( 1 teaspoon ) draw antibody test . Antibodies create immune system may attack foreign cell substance , study drug . At 4 week ( +/- 2 week ) 3 month ( +/- 3 week ) vaccine , blood ( 2 teaspoon ) draw antibody testing , cytokine testing , test immune system . Length Study : You take study drug 2 year . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . End Study : °Blood ( 2 teaspoon ) draw antibody test cytokine testing . This investigational study . Lenalidomide FDA approve commercially available treatment multiple myeloma , myelodysplastic syndrome mantle cell lymphoma . The use help prevent infection improve immunoglobulin level use combination flu pneumonia vaccine investigational . Up 35 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>1 . Chronic lymphocytic leukemia ( CLL ) patient IgG le 500 mg/dl with/without symptom either untreated previously treat , regardless response , least 6 month prior therapy ( include mAb ) .. 2 . ECOG/WHO performance status 02 . 3 . Adequate renal function indicate serum creatinine equal le 2 mg/dl . 4 . Adequate hepatic function indicate total bilirubin equal less 2 mg/dl ALT equal less two time upper limit normal . 5 . Disease free prior malignancy 3 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . Patients malignancy indolent behavior prostate cancer treat radiation surgery enrol study long reasonable expectation cure treatment modality receive . 6 . Females childbearing potential ( FCBP ) . A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) &gt; 7 . FCBP must negative serum urine pregnancy test sensitivity least 50 mlU/mL within 1014 day prior within 24 hour start lenalidomide heterosexual intercourse begin two acceptable method birth control , one highly effective method one additional effective method time , least 28 day start take lenalidomide . 8 . FCBP must also agree ongoing pregnancy test ( weekly first four week every 28 day therapy discontinuation treatment ) . 9 . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 10 . Patients must 18 year age old . 11 . All study participant must register mandatory Revlimid REMS® program , willing able comply requirement REMS® program . 12 . Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS® program . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) . 1 . Known sensitivity lenalidomide thalidomide derivative . 2 . History GuillainBarre within 6 week previous influenza vaccination . 3 . Patient steroid therapy . 4 . Documented prolymphocytic leukemia ( prolymphocytes 55 % blood ) Richter 's transformation . 5 . Known positivity HIV active hepatitis B C. 6 . Pregnant breast feeding female . 7 . History tuberculosis treat within last five year recent exposure tuberculosis . 8 . Any serious medical condition , laboratory abnormality psychiatric illness place subject unacceptable risk he/she participate study . 9 . Patients recent history deep vein thrombosis ( DVT ) pulmonary embolus ( PE ) , six month prior enrollment eligible study . 10 . Subjects currently active hepatic biliary disease ( exception patient Gilbert 's syndrome ) . 11 . Patients severe allergic reaction ( e.g. , anaphylaxis ) previous dose influenza vaccine vaccine component , include egg protein . 12 . Moderate severe acute illness without fever . 13 . Use experimental drug therapy within 28 day baseline . 14 . Concurrent use anticancer agent treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hematologic Disorder</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Hypogammaglobulinemia</keyword>
	<keyword>Impaired Response Vaccinations</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>Immune system 's function</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Flu vaccine</keyword>
	<keyword>TIV</keyword>
	<keyword>Pneumonia vaccine</keyword>
</DOC>